Clinical Trials Logo

CERVICAL NEOPLASMS clinical trials

View clinical trials related to CERVICAL NEOPLASMS.

Filter by:
  • None
  • Page 1

NCT ID: NCT05824494 Not yet recruiting - Cervical Cancer Clinical Trials

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Start date: June 2023
Phase: Phase 2
Study type: Interventional

This is a phase II trial of combination therapy of cadonilimab(Bispecific Anti-PD-1/CTLA-4 Antibody) plus nab-Paclitaxel in patients with recurrent or metastatic cervical cancer that had failed PD-1/PD-L1 blockade therapy. As a bispecific antibody against PD-1 and CTLA-4, cardonirimab can not only induce the production of a large number of T cells in the early stage of immune response by antagonizing CTLA-4, but also block PD-1 and PD-L1/L2 combination. Thereby restoring the killing function of T cells to tumor cells and reducing the exhaustion of T cells.The hypothesis is the combination of cadonilimab and nab-Paclitaxel will overcome PD-1/PD-L1 blockade-resistance to enhance the response of patients with persistant, recurrent or metastatic cervical cancer.

NCT ID: NCT04266093 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Start date: May 8, 2020
Phase:
Study type: Observational

Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of people who have had the treatment. This study collects data on people who have had gene therapy and sends it to the FDA. The data does not include participants names. Objective: To contact current or past participants of gene therapy protocols at least once a year for up to 15 years to ensure they have not had any harmful side effects. Eligibility: People aged 18 and older who have had gene therapy in a National Cancer Institute study Design: Participants will give their address and telephone number. They will also give and the address and phone number of 1 or 2 other people who will know where they are. For the first year after gene therapy, participants will give blood samples 3 times (at 3, 6, and 12 months). For the next 4 years, they may have a physical exam and laboratory tests with a home physician. They will get a kit to mail in blood samples. Or they can visit the NIH Clinical Center. They will be asked if they have had any signs of neurological, autoimmune, or blood disorders, or any new cancers. For years 6 to 15, participants will be contacted yearly via phone or email and asked questions about their health. They may give blood samples. When the participant dies, if researchers think the death was caused by gene therapy, they will ask the participant s family to allow an autopsy. ...

NCT ID: NCT04096911 Recruiting - Cervical Cancer Clinical Trials

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Start date: July 31, 2019
Phase: Phase 2
Study type: Interventional

The investigators propose to evaluate the efficacy of the combination of Pd-1 Monoclonal Antibody and HPV Vaccine in the patients with cervical cancer who fails in or can not endure the standard treatment

NCT ID: NCT02267876 Completed - Clinical trials for Human Papillomavirus

Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens

Start date: October 2014
Phase:
Study type: Observational

The purpose of the study is to assess the cumulative disease detection of greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) and greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) in the subjects over 3 years using the subject's HPV status and cytology status from the BDS-USHPV baseline results

NCT ID: NCT01627288 Completed - Clinical trials for Cancer of the Cervix

Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)

IDEAL
Start date: June 4, 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of integrated boost radiation therapy when given with concurrent chemotherapy (cisplatin).

NCT ID: NCT00950261 Withdrawn - Cervical Neoplasms Clinical Trials

Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The standard postoperative treatment for patients with cervical cancer who had high-risk factors is chemoradiation. Generally, weekly cisplatin or 5FU+cisplatin every 3 week have been used as chemotherapy regimens of chemoradiation. Based on their experience, the investigators hypothesized that tri-weekly cisplatin could be superior to weekly cisplatin. Therefore, the investigators are going to perform the efficacy study of postoperative, tri-weekly cisplatin chemoradiation for patients with cervical cancer.

NCT ID: NCT00916500 Completed - CERVICAL NEOPLASMS Clinical Trials

Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer

Start date: March 2006
Phase: Phase 2
Study type: Interventional

Concurrent chemoradiation (CCRT) is the standard therapy for locally advanced cervical cancer. However, the most effective chemotherapy regimen is controversial. Weekly cisplatin, hydroxyurea + cisplatin, 5-FU + cisplatin are tested in clinical trials. Weekly cisplatin needs frequent hospital visits and had a poor compliance profile in korea. Combination chemotherapy regimens had more adverse effects than weekly cisplatin without improving outcomes. We conducted a retrospective analysis comparing weekly cisplatin with cisplatin every 3 weeks and observed favorable outcome for cisplatin every 3 weeks regimen (still not published). Therefore, we designed a phase 2 trial evaluating the efficacy and feasibility of CCRT with cisplatin every 3 weeks.

NCT ID: NCT00190528 Terminated - Cervical Neoplasms Clinical Trials

A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer

Start date: February 2002
Phase: Phase 3
Study type: Interventional

To investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II cervical cancer